---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-088700"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-19T00:31:28.894024+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FDA alignment opens third dosing cohort for Perspective's 212Pb-VMT-α-NET NET trial at 6 mCi (20% higher)

## Summary
- FDA opened Cohort 3 at 6 mCi (20% higher than Cohort 2) per dose for patients weighing >60 kg.
- No DLTs observed among 42 patients treated; no grade ≥4 AEs; anti-tumor activity in 4 of 7 Cohort 2 DLT-evaluable patients.
- Dosimetry sub-study using [203Pb]VMT-α-NET presented at SNMMI 2025 shows feasibility and tolerable absorbed doses.
- Company on track to submit further clinical updates in 2H 2025, including longer safety and anti-tumor activity data.

## SEC filing metadata
- accession: 0000950170-25-088700
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017025088700/0000950170-25-088700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017025088700/catx-20250621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-088700
- JSON: https://secwatch.observer/filing/0000950170-25-088700.json
- Plain text: https://secwatch.observer/filing/0000950170-25-088700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.